TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9326194
Drug: mercaptopurine (lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: mercaptopurine (lower doses)
Study: 9326194
Drug: early intensification
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: early intensification treatment
Study: 9326194
Drug: myelosuppression during
Normalized name: Pro-C-Dure 6 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: myelosuppression during treatment
Study: 2853091
Drug: Acebutolol (A)
DrugBank: Acebutolol (DB01193)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acebutolol (A) 400 mg once-daily
Study: 2853091
Drug: Enalapril (E)
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalapril (E) 20 mg once-daily
Study: 2853091
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Acebutolol and Enalapril (A + E)
Study: 24200275
Drug: Myrin®-P Forte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myrin®-P Forte (FDC tablet containing rifampicin 150 mg, isoniazid 75 mg, ethambutol hydrochloride 275 mg, pyrazinamide 400 mg)
Study: 24200275
Drug: Individual products
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual products in loose combination (rifampicin, isoniazid, ethambutol hydrochloride, pyrazinamide)
Study: 21169471
Drug: Inhaled denufosol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled denufosol, 60 mg, three times daily (n = 178)
Study: 18658109
Drug: Inhaled aztreonam
Normalized name: aztreonam Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled aztreonam lysine (AZLI) 75 mg, twice or three times daily for 28 days
Study: 18658109
Drug: Inhaled aztreonam
Normalized name: aztreonam Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled aztreonam lysine (AZLI) 75 mg
Study: 26971081
Drug: Sertraline 100
Normalized name: sertraline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 100 mg/day
Study: 8957034
Drug: Low-dose ramipril
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ramipril (1.25 mg/d)
Study: 8957034
Drug: High-dose ramipril
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ramipril (5 mg/d)
Study: 22446739
Drug: Standard support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard support with nicotine replacement therapy
Study: 22446739
Drug: No nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No nicotine replacement therapy
Study: 20735791
Drug: Silodosin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silodosin (4 mg, twice daily for 4 weeks)
Study: 20735791
Drug: Tamsulosin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.2 mg, once daily for 4 weeks)
Study: 15702440
Drug: rhGH in
Normalized name: rhGH
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH in combination with metformin (MGH)
Study: 15702440
Drug: Metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin + Placebo (MP)
Study: 12541165
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg/die
Study: 12541165
Drug: Ceftriaxone 2
Normalized name: ceftriaxone 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 2 g/die
Study: 1813436
Drug: 15-deoxyspergualin (DSG)
Normalized name: Deoxyspergualin
DrugBank: Deoxyspergualin (DB12991)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-deoxyspergualin (DSG) at 3 mg/kg/day for 5 days
Study: 1813436
Drug: 15-deoxyspergualin (DSG)
Normalized name: Deoxyspergualin
DrugBank: Deoxyspergualin (DB12991)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-deoxyspergualin (DSG) at 5 mg/kg/day for 5 days
Study: 1813436
Drug: 15-deoxyspergualin (DSG)
Normalized name: Deoxyspergualin
DrugBank: Deoxyspergualin (DB12991)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-deoxyspergualin (DSG) at 7 mg/kg/day for 5 days
Study: 1813436
Drug: 15-deoxyspergualin (DSG)
Normalized name: Deoxyspergualin
DrugBank: Deoxyspergualin (DB12991)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-deoxyspergualin (DSG) at 3-5 mg/kg/day
Study: 6613913
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg daily dietary aluminum (test diet)
Study: 6613913
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg daily dietary aluminum (control diet)
Study: 31028327
Drug: High-viscosity glass-ionomer,
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-viscosity glass-ionomer, atraumatic restorative treatment method (HVGIC/ART)
Study: 23669281
Drug: YIC (HBsAg-HBIG
Approvals — FDA: no, EMA: no, PMDA: no
Description: YIC (HBsAg-HBIG immunogenic complex therapeutic vaccine)
Study: 19176737
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with high-dose iron-folic acid for 90 days and single-dose (500 mg) mebendazole
Study: 19176737
Drug: Enhanced treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced treatment with 100 mg mebendazole twice daily for 3 days
Study: 19176737
Drug: 90 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 days of daily multivitamins
Study: 19176737
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of enhanced mebendazole and multivitamins
Study: 17971666
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg GGA t.i.d. for 2 weeks
Study: 17971666
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg CIT b.i.d. for 2 weeks
Study: 15600244
Drug: Antifungal agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antifungal agents
Study: 7627383
Drug: Octreotide (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (0.1 mg injected subcutaneously three times a day)
Study: 7627383
Drug: Control (conservative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (conservative treatment alone)
Study: 1790735
Drug: Ponalrestat (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponalrestat (600 mg daily)
Study: 7041934
Drug: ibopamine (SB
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibopamine (SB 7505, a new oral dopaminergic drug)
Study: 26928164
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of suboccipital inhibitory pressure and spinal manipulation
Study: 19618661
Drug: Cyproheptadine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproheptadine administration (n = 10)
Study: 15002546
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of a balanced mixture of essential and non-essential amino acids at a rate of 0.1 g/kg/hour for 3 hours.
Study: 7625114
Drug: Intranasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration of trivalent cold-adapted recombinant influenza virus vaccine containing type A (H1N1 and H3N2) and B viruses.
Study: 7625114
Drug: Intranasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration of trivalent cold-adapted recombinant influenza virus vaccine.
Study: 20170948
Drug: benazepril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: benazepril (20 mg) plus amlodipine (5 mg)
Study: 20170948
Drug: benazepril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: benazepril (20 mg) plus hydrochlorothiazide (12.5 mg)
Study: 12200762
Drug: Fiber and
Normalized name: Nutritional Supplement Oral Liquid [PEDIASURE WITH FIBER AND FOS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiber and vitamin combination therapy
Study: 7589999
Drug: omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole 20 mg for 8 weeks
Study: 7232006
Drug: Fentanyl (narcotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (narcotic analgesic)
Study: 27314762
Drug: Aloe vera
Normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloe vera (systemic juice and topical gel) for 3 months
Study: 27314762
Drug: Intralesional injection
Normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injection of hydrocortisone and hyaluronidase with antioxidant supplements for 6 weeks and 3 months respectively
Study: 25110231
Drug: Intravenous alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alcohol administration at two target blood alcohol concentrations (40 and 80 mg%)
Study: 25043153
Drug: Gabapentin 300
Normalized name: gabapentin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 300 mg twice a day and dexamethasone (dex)
Study: 12196048
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) injections of morphine every 4 hours as needed
Study: 9484732
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (intravenous epirubicin hydrochloride: 8 doses of 40 mg/m2 each at 6-week intervals; transarterial chemotherapy: 3 courses with a maximum dose of 20 mL each at 2-month intervals)
Study: 14987883
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant treatment (control group)
Study: 11504165
Drug: Perindopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4 mg once a day)
Study: 1395119
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg b.d.)
Study: 11309552
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 mg once a day)
Study: 2505715
Drug: Combined hydrochlorothiazide
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined hydrochlorothiazide + amiloride (50 mg + 5 mg once a day)
Study: 2505715
Drug: Perindopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4 mg once a day) with diuretic
Study: 2505715
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg b.d.) with diuretic
Study: 2505715
Drug: Perindopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4 mg once a day) with atenolol
Study: 2505715
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 mg once a day) with diuretic
Study: 2505715
Drug: Perindopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4 mg once a day) with beta-blocker
Study: 2505715
Drug: Combined hydrochlorothiazide
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined hydrochlorothiazide + amiloride (50 mg + 5 mg once a day) with beta-blocker
Study: 1658962
Drug: Heparin-Dihydergot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-Dihydergot
Study: 27349901
Drug: BI 811283
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 811283 (Aurora B kinase inhibitor) administered via 24‐h infusion on Days 1 and 15 of a 4‐week cycle (schedule A) or Day 1 of a 3‐week cycle (schedule B)
Study: 27349901
Drug: BI 811283
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 811283 (Aurora B kinase inhibitor)
Study: 18260939
Drug: Spironolactone (25-75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (25-75 mg/day)
Study: 12116339
Drug: Standard ICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ICE chemotherapy
Study: 6773727
Drug: Low-dose insulin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose insulin therapy
Study: 21616512
Drug: High-dose insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose insulin therapy
Study: 30333270
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of DLBS1033 (3 x 490 mg)
Study: 30333270
Drug: Repeated administration
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated administration of DLBS1033 (3 x 490 mg/day for 3 days)
Study: 20402381
Drug: Tocilizumab (TCZ)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab (TCZ) monotherapy (8 mg/kg every 4 weeks)
Study: 20191522
Drug: Methotrexate monotherapy
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate monotherapy
Study: 18756880
Drug: Corticosteroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid therapy (5 mg Prednisolonacetate, anterior H‐inject, Winthorp) administered via parabulbar injections every day/five days
Study: 18756880
Drug: Regular polyvitamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular polyvitamine therapy (Lutein, Beta Karoten, Vitamin E)
Study: 1852664
Drug: Danazol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (100 mg twice daily)
Study: 30972712
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (non-event patients with ≥ 180 days of warfarin exposure)
Study: 28792105
Drug: TPTNS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPTNS plus 20 mg trospium chloride daily
Study: 26807631
Drug: Intravitreal injections
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injections of rtPA, perfluoropropane (C3F8) gas, and bevacizumab (n = 12)
Study: 26807631
Drug: Vitrectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitrectomy with subretinal rtPA administration, intravitreal C3F8 gas, and bevacizumab (n = 12)
Study: 21198965
Drug: High biotin
Normalized name: Biotin
DrugBank: Biotin (DB00121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High biotin diet (2000 μg/kg)
Study: 21198965
Drug: High Zn
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Zn diet (150 mg/kg)
Study: 21198965
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (300 μg biotin and 50 mg Zn/kg)
Study: 21198965
Drug: Wet litter
Normalized name: BITTER MELON
DrugBank: Momordica charantia fruit (DB14265)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wet litter exposure (27% DM for 8 h daily)
Study: 21135293
Drug: Metoprolol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (1 to 3 mg/h for 48 hours)
Study: 21135293
Drug: Amiodarone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (15 mg/kg daily, max 1000 mg for 48 hours)
Study: 16301237
Drug: Spinal block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal block with 5 mg of 0.5% bupivacaine (LDS)
Study: 16301237
Drug: Spinal block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal block with 2.5 mg of 0.5% bupivacaine plus 25 mug of fentanyl (SDS)
Study: 16301237
Drug: Spinal block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal block with 2.5 mg of bupivacaine plus 25 mug of fentanyl (SDS)
Study: 7621007
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with ischemic cardiopathy (no calcium antagonists)
Study: 2658574
Drug: No empiric
Approvals — FDA: no, EMA: no, PMDA: no
Description: No empiric antifungal therapy (control)
Study: 5302329
Drug: High-potency whole-cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-potency whole-cell cholera vaccine
Study: 23362293
Drug: Cholera vaccine
Normalized name: Cholera Vaccine
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholera vaccine
Study: 31043161
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of plant sterols (PS) and omega‐3 fatty acids
Study: 31043161
Drug: Placebo (soy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (soy bean powder plus placebo capsules)
Study: 27749740
Drug: Pueraria mirifica
Normalized name: PUERARIA MIRIFICA ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pueraria mirifica gel
Study: 27749740
Drug: Conjugated estrogen
Normalized name: Conjugated estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated estrogen cream (CEE)
Study: 12548439
Drug: Anti-inflammatory diet
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-inflammatory diet (AID) with arachidonic acid intake of less than 90 mg/day
Study: 12548439
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil capsules (30 mg/kg body weight)
Study: 1848385
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (Logiparin)
Study: 6472365
Drug: Acetohydroxamic acid
Normalized name: Acetohydroxamic Acid
DrugBank: Acetohydroxamic acid (DB00551)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetohydroxamic acid (15 mg per kilogram of body weight per day, in divided oral doses)
Study: 17175820
Drug: Ibuprofen (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (400 mg every 8 hours)
Study: 27384376
Drug: Acetaminophen (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (1 g every 6 hours)
Study: 27384376
Drug: Both Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Both Ibuprofen and Acetaminophen
Study: 25717250
Drug: LC+IOC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: LC+IOC treatment
Study: 25717250
Drug: Routine LC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine LC treatment
Study: 23981814
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of inositol and alpha lipoic acid
Study: 17708158
Drug: Cold blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold blood cardioplegia solution with Technetium (Tc-99m) tracer
Study: 17708158
Drug: Cold blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold blood cardioplegia solution
Study: 15113965
Drug: Daily supervised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supervised iron supplementation [3-6 mg/(kg.d)]
Study: 15113965
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly supervised iron supplementation [6-12 mg/(kg.wk)]
Study: 15113965
Drug: Daily unsupervised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily unsupervised iron supplementation
Study: 15113965
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly unsupervised iron supplementation
Study: 9701417
Drug: Orciprenaline sulphate
Normalized name: orciprenaline
DrugBank: Orciprenaline (DB00816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orciprenaline sulphate (2.25 mg)
Study: 7838917
Drug: Flumazenil (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (2 mg in saline)
Study: 3171331
Drug: Topical prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical prostaglandin E2 (0.02% solution)
Study: 3171331
Drug: Topical prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical prostaglandin E2
Study: 25569624
Drug: Skimmed milk
Normalized name: Calcium fortified skimmed milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skimmed milk (600 mL)
Study: 25569624
Drug: Orange drink
Normalized name: Orange
DrugBank: Orange (DB10549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orange drink (600 mL)
Study: 24660603
Drug: Chinese medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medication (established Chinese herbal formulas)
Study: 24660603
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication (leukotriene receptor antagonist and bronchial relaxant)
Study: 18483475
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment with enhanced food monitoring accuracy (EFMA)
Study: 18483475
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment with enhanced food monitoring accuracy (EFMA) plus reduced energy density eating (REDE)
Study: 9374583
Drug: vapocoolant spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: vapocoolant spray + distraction
Study: 9374583
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream + distraction
Study: 8247189
Drug: Prednisone 60
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone 60 mg/day
Study: 3033180
Drug: enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril 20 mg daily
Study: 12107602
Drug: atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol 50 mg daily
Study: 3033180
Drug: enalapril (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril (higher dose if diastolic BP > 90 mmHg)
Study: 3033180
Drug: atenolol (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol (higher dose if diastolic BP > 90 mmHg)
Study: 29923305
Drug: LI85008F (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: LI85008F (900 mg/d in two divided doses)
Study: 24225560
Drug: L-arginine (ARG)
DrugBank: L-arginine (DB17289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (ARG)
Study: 25380894
Drug: Other formulations
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other formulations of mycophenolate
Study: 17852173
Drug: Internet-based cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive-behavioral therapy for complicated grief